Due to increasing evidence suggesting that metabolic reprogramming and elevated lactate levels may play a significant role in the pathogenesis of IPF, pharmacological inhibition of LDHA and LDH5 has emerged as a potential strategy to inhibit myofibroblast differentiation in IPF [107,108]. This evidence concerns the gene LDHA and idiopathic pulmonary fibrosis.